Skip to main content
Top
Published in: Infectious Diseases and Therapy 1/2021

Open Access 01-03-2021 | Community-Acquired Pneumonia | Original Research

Comparison of Prospective and Retrospective Methods of a Tigecycline Post-Marketing Surveillance Study in the Safety Outcomes of Patients with Complicated Skin Structure Infection, Complicated Intraabdominal Infection and Community-Acquired Pneumonia

Authors: Whanhui Chi, Hye Jung Lee, Yong Pil Chong

Published in: Infectious Diseases and Therapy | Issue 1/2021

Login to get access

Abstract

Introduction

Safety data can be collected through prospective and retrospective methods during post-marketing surveillance (PMS). This study aimed to compare prospective and retrospective methods in terms of examining safety data from PMS of tigecycline.

Methods

This PMS study was an open-label, noncomparative, observational, noninterventional and multicenter study of patients who received tigecycline for infections. From July 2007 to April 2015, 3172 patients were included in this study, of which 738 were enrolled prospectively and 2434 retrospectively. To reduce selection bias, demographic and baseline characteristics were adjusted using 1:2 propensity score matching.

Results

After propensity score matching, data from 1446 patients were analyzed. The incidences of adverse events (AEs) and serious AEs (SAEs) were determined to be significantly higher in the prospective method compared with those of the retrospective method (P < 0.001 and P = 0.004, respectively). However, no significant differences in the incidences of adverse drug reactions (ADRs) and serious ADRs (SADRs) were detected between the two groups (P = 0.09 and P = 0.33, respectively). In a subgroup analysis of 360 patients from 14 hospitals involved in both prospective and retrospective methods, the incidence of AEs was found to be significantly higher using the prospective method compared with when the retrospective method was used (P < 0.001), but there were no significant differences in ADRs (P = 0.14), SAEs (P = 0.24) and SADRs.

Conclusion

In general, the prospective method can detect safety data effectively in a PMS study, whereas retrospective data collection may be an alternative option in collecting ADR data when a prospective PMS study is not deemed feasible.
Appendix
Available only for authorised users
Literature
1.
go back to reference Park EJ. The quality control of post-authorization study of re-examination in Korea. J Korean Acad Manag Care Pharm. 2015;4(1):1–6. Park EJ. The quality control of post-authorization study of re-examination in Korea. J Korean Acad Manag Care Pharm. 2015;4(1):1–6.
2.
go back to reference KFDA. Guideline for re-examination on drugs including new drugs. Cheongju: KFDA; 2012. KFDA. Guideline for re-examination on drugs including new drugs. Cheongju: KFDA; 2012.
6.
go back to reference Fomin P, Beuran M, Gradauskas A, Barauskas G, Datsenko A, Dartois N, Ellis-Grosse E, Loh E. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg. 2005;3(1):35–47.CrossRef Fomin P, Beuran M, Gradauskas A, Barauskas G, Datsenko A, Dartois N, Ellis-Grosse E, Loh E. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg. 2005;3(1):35–47.CrossRef
7.
go back to reference Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, Babinchak T, Ellis-Grosse EJ, Loh E, the 301 Study Group. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials. gov Identifier: NCT00081744]. BioMed Central Infect Dis. 2005;51:88.CrossRef Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, Babinchak T, Ellis-Grosse EJ, Loh E, the 301 Study Group. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials. gov Identifier: NCT00081744]. BioMed Central Infect Dis. 2005;51:88.CrossRef
10.
go back to reference Ukai T, Shikata S, Nakayama T, Takemura YC. A comparison of the results of prospective and retrospective cohort studies in the field of digestive surgery. Jpn J Surg. 2017;47(7):789–94. Ukai T, Shikata S, Nakayama T, Takemura YC. A comparison of the results of prospective and retrospective cohort studies in the field of digestive surgery. Jpn J Surg. 2017;47(7):789–94.
11.
go back to reference Sedgwick P. Retrospective cohort studies: advantages and disadvantages. BMJ. 2014;348:g1072.CrossRef Sedgwick P. Retrospective cohort studies: advantages and disadvantages. BMJ. 2014;348:g1072.CrossRef
12.
go back to reference Weinger M, Slagle J, Ordonez N. Retrospective data collection and analytical techniques for patient safety studies. J Biomed Inform. 2003;36(1–2):106–19.CrossRef Weinger M, Slagle J, Ordonez N. Retrospective data collection and analytical techniques for patient safety studies. J Biomed Inform. 2003;36(1–2):106–19.CrossRef
Metadata
Title
Comparison of Prospective and Retrospective Methods of a Tigecycline Post-Marketing Surveillance Study in the Safety Outcomes of Patients with Complicated Skin Structure Infection, Complicated Intraabdominal Infection and Community-Acquired Pneumonia
Authors
Whanhui Chi
Hye Jung Lee
Yong Pil Chong
Publication date
01-03-2021
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 1/2021
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-021-00398-7

Other articles of this Issue 1/2021

Infectious Diseases and Therapy 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.